Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
Kawita M. S. Kanhai(Centre for Human Drug Research), Geert Jan Groeneveld(Leiden University Medical Center), Sandrin C. Bergheanu, Yorick L. Wagenaar(Centre for Human Drug Research), Mike P. Wattjes(Humboldt-Universität zu Berlin), Jenny A. Nij Bijvank(Amsterdam Neuroscience), Axel Petzold(University College London), Jacob Hesterman(Invicro (United States)), Erica S. Klaassen(Centre for Human Drug Research), Ajay Verma(Biogen (United States)), Bernard M.J. Uitdehaag(Amsterdam Neuroscience), K.Y. Lim(Centre for Human Drug Research), Laurentius J. van Rijn(OLVG)
Cited by 20
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
|Nature Reviews Neurology|2022|809
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
|Nature Genetics|2009|807
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
|The Lancet Neurology|2021|646